Guidelines for diagnosis and management of Beta-thalassemia intermedia

Area of Science:

• Hematology
• Genetics
• Pediatric Medicine

Background:

• Beta-thalassemia intermedia (β-TI) is a heterogeneous genetic blood disorder.
• Its clinical severity ranges between thalassemia minor and major.
• Various genetic defects contribute to β-TI, leading to diverse clinical presentations.

Purpose of the Study:

• To review the clinical manifestations of β-TI.
• To discuss the complications associated with β-TI.
• To explore genetic defects and unmet treatment needs in β-TI.

Main Methods:

• Literature review of clinical and laboratory data.
• Analysis of genetic defects causing β-TI.
• Synthesis of current and potential treatment strategies.

Main Results:

• β-TI patients may exhibit skeletal deformities, growth retardation, splenomegaly, extramedullary hematopoiesis, heart failure, and endocrine disorders.
• Diagnosis relies on clinical evaluation and laboratory findings.
• Effective management is crucial to prevent long-term complications.

Conclusions:

• Precise diagnosis and management are vital for β-TI patients.
• Treatment options include hydroxyurea, transfusions, splenectomy, and stem cell transplantation.
• Iron chelation therapy is often necessary, even in non-transfused patients, highlighting ongoing treatment challenges.